A 3907
Alternative Names: A-3907; IPN-60250Latest Information Update: 28 Apr 2024
At a glance
- Originator Albireo Pharma
- Developer Albireo Pharma; Ipsen
- Class Anti-inflammatories; Antifibrotics; Hepatoprotectants
- Mechanism of Action Sodium-bile acid cotransporter inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Primary sclerosing cholangitis
- Preclinical Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis
- No development reported Primary biliary cirrhosis
Most Recent Events
- 28 Apr 2024 No recent reports of development identified for phase-I development in Primary-biliary-cirrhosis(In volunteers) in USA (PO)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Primary-sclerosing-cholangitis(In volunteers) in USA (PO)
- 21 Jun 2023 Pharmacodynamics data from a preclinical study in Cholestasis presented at the European Association for the Study of the Liver Congress (EASL-2023)